EGFR and breast cancer: In a study on breast cancer cells exhibiting MDR, targeted liposomes loaded with doxorubicin and functionalized with anti-EGFR (epidermal growth factor receptor) antibodies were able to overcome resistance and showed enhanced cellular uptake and cytotoxicity compared to non-targeted formulations [75].